Xiaoqiu Yang

Xiaoqiu Yang


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2016 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
XYXiaoqiu Yang
Xiaoqiu Yang
HMHuilai Miao
Huilai Miao
SFShuo Fang
Shuo Fang
TFTao Fang
Tao Fang
NCNianping Chen
Nianping Chen
MLMingyi Li
Mingyi Li
Aberrant expression of CDKN3 may be involved in carcinogenesis of liver cancer. The effect of CDKN3 on tumorigenesis and the molecular mechanisms involved have not been fully elucidated. Immunohistochemistry was performed to detect CDKN3 expression levels in tumor tissues. CDKN3 siRNA was used to knockdown CDKN3 in QGY7701 hepatocellular carcinoma (HCC) cells. Colony formation assay was used to measure the clonogenic capacity of the tumor cells. Cell viability was determined by MTT assay. Logistic regression was performed to analyze the association between CDKN3 expression level and the HCC clinical pathology index. The CDKN3 expression level was significantly decreased in HCC tumor tissues compared with normal liver tissue and liver cirrhosis tissue. Additionally, CDKN3 expression was negatively‑associated with the pathological stage of the tumor. Inhibition of CKDN3 promoted the clonogenic capacity and chemotherapeutic tolerance in HCC tissues compared with controls. Knockdown of CDKN3 resulted in downregulation of p53 and p21 protein levels, whereas, AKT serine/threonine kinase 1 expression was upregulated. Thus, CDKN3 expression may reduce the survival of tumor cells and alter the sensitivity to therapeutic agents via the AKT/P53/P21 signaling pathway. Therefore, CDKN3 may be involved in tumor differentiation and self-renewal.

14 October 2019 in World Journal of Gastroenterology
Verified
Journal Article
Closed access
XYXiaoqiu Yang
Xiaoqiu Yang
JDJia-Liang Dai
Jia-Liang Dai
MTMao-Hua Tang
Mao-Hua Tang
MYMu-Shi Ye
Mu-Shi Ye
SFShuo Fang
Shuo Fang
BACKGROUND Hepatocellular carcinoma (HCC) has become a great threat for people's health. Many long noncoding RNAs are involved in the pathogenesis of HCC. SNHG15, as a tissue specific long noncoding RNAs, has been studied in many human cancers, except HCC. AIM To explore the regulatory mechanism of SNHG15 in HCC. METHODS In the present research, 101 HCC patient samples, two HCC cell lines and one normal liver cell line were used. RT-qPCR and Western blot analysis were applied to detect SNHG15, miR-490-3p and histone deacetylase 2 (HDAC2) expression. The regulatory mechanism of SNHG15 was investigated using CCK8, Transwell and luciferase reporter assays. RESULTS Our research showed that up-regulation of SNHG15 was found in HCC and was related to aggressive behaviors in HCC patients. Moreover, knockdown of SNHG15 restrained HCC cell proliferation, migration and invasion. In addition, SNHG15 served as a molecular sponge for miR-490-3p. Further, miR-490-3p directly targets HDAC2. HDAC2 was involved in HCC progression by interacting with the SNHG15/miR-490-3p axis. CONCLUSION In conclusion, long noncoding RNA SNHG15 promotes HCC progression by mediating the miR-490-3p/HDAC2 axis in HCC.

15 August 2015
Verified
Journal Article
Closed access
XYXiaoqiu Yang
Xiaoqiu Yang
HHHai-Li Huang
Hai-Li Huang
MHMin Hu
Min Hu
SWSi-Jie Wang
Si-Jie Wang
HHHui-Juan He
Hui-Juan He
MLMing-Yi Li
Ming-Yi Li

3 November 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
HHHuijuan He
Huijuan He
JDJialiang Dai
Jialiang Dai
JFJialing Feng
Jialing Feng
QHQiang He
Qiang He
XCXuling Chen
Xuling Chen
HHHaili Huang
Haili Huang

28 July 2020 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
XYXiaoqiu Yang
Xiaoqiu Yang
SFShuo Fang
Shuo Fang
GCGuanhe Cai
Guanhe Cai
JDJialiang Dai
Jialiang Dai
GLGuotai Lin
Guotai Lin
MLMingyi Li
Mingyi Li
Objective: Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide. This study investigated the relationship between cyclin-dependent kinase inhibitor (CDKN)3 and prognosis and pathological characteristics in HCC patients to determine whether it could be used as a prognostic factor and/or therapeutic target for HCC drug development. Methods: We previously showed that CDKN3 is deregulated in HCC tumor samples. Here, bioinformatics analysis was used to assess the relationship between CDKN3 gene expression and the characteristics of HCC patients from Gene Expression Omnibus and The Cancer Genome Atlas databases. Additionally, CDKN3 expression was silenced by small interfering RNA to determine its effect on HCC cell proliferation and on HCC cell sensitivity to adriamycin chemotherapy. Results: Bioinformatics analysis showed a negative correlation between CDKN3 expression and both disease-free survival and overall survival. CDKN3 silencing did not significantly suppress the proliferation of HCC cells, but did decrease their sensitivity to adriamycin. Conclusions: CDKN3 may have a dual role during the development of HCC, and could be used as an independent prognostic factor and therapeutic target for HCC treatment.

28 January 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
XLXiao‐Guang Liu
Xiao‐Guang Liu
HXHao Xu
Hao Xu
Ming ChenMing Chen
Ming Chen
XTXiaoyu Tan
Xiaoyu Tan
XCXiao‐Feng Chen
Xiao‐Feng Chen
NCNian‐Ping Chen
Nian‐Ping Chen
Previous studies have shown that forkhead box P4 antisense RNA 1 (FOXP4‐AS1) is dysregulated in tumor tissues and can serve as a prognostic indicator for multiple cancers. However, the clinical significance of FOXP4‐AS1 in pancreatic ductal adenocarcinoma (PDAC) remains unclear. The goal of this study is to recognize the possible clinical significance of long noncoding RNA FOXP4‐AS1 in patients with early stage PDAC. A total of 112 patients from The Cancer Genome Atlas (TCGA) PDAC cohort, receiving RNA sequencing, were involved in the study. Survival analysis, functional mechanism, and potential small molecule drugs of target therapy of FOXP4‐AS1 were performed in this study. Survival analysis in TCGA PDAC cohort suggested that patients with high FOXP4‐AS1 expression had significantly augmented possibility of death than in PDAC patients with lower FOXP4‐AS1 expression (adjusted P = .008; adjusted HR = 2.143, 95% CI = 1.221‐3.760). In this study, a genome‐wide RNA sequencing dataset was used to identify 927 genes co‐expressing with FOXP4‐AS1 in PDAC tumor tissues. A total of 676 differentially expressed genes were identified between different FOXP4‐AS1 expression groups. Functional enrichment analysis of these genes and gene set enrichment analysis for PDAC genome‐wide RNA sequencing dataset was done. We have found that FOXP4‐AS1 may function in PDAC by participating in biological processes and pathways including oxidative phosphorylation, tricarboxylic acid cycle, classical tumor‐related pathways such as NF‐kappaB as well as Janus kinase/signal transducers in addition to activators of transcription, cell proliferation, and adhesion. In addition, we also screened two potential targeted therapeutic small molecule drugs (dimenhydrinate and metanephrine) for FOXP4‐AS1 in PDAC. In conclusion, our present study demonstrated that higher expression of FOXP4‐AS1 in PDAC tumor tissues were related with an inferior medical outcome. Through multiple genome‐wide approaches, we identified the potential molecular mechanisms of FOXP4‐AS1 in PDAC and two targeted therapeutic drugs for it.